7009 Background: Survival outcomes of 2^nd line mCRC therapy for OA are poorly understood. We evaluated the rates and survival outcomes of 2^nd line therapy among OA age 70+ compared to younger adults (YA) age < 70 following progression on 1^st line clinical trials. Methods: Associations between clinical characteristics of pts with available treatment data after progression on 10 of 23 1^st line ARCAD trials, time to initial progression (TTiP) and 2^nd line therapy were evaluated. Time to progression (TTP) and overall survival (OS) were compared between OA and YA enrolled on 2^nd line trials by Cox regression, adjusting for age, sex, ECOG PS, number of metastatic sites, presence of metastasis in lung/liver/peritoneum. Results: Sixteen percent of 1^st line ARCAD trial participants were age 70+ (n = 870). Data for 2^nd line therapy was available for 60.6% pts (3206/5289). Each additional decade of life was associated with 11% lower odds of receiving 2^nd line therapy in multivariate analysis (p = 0.0117). OA participating in 2^nd line trials (7.9% age 75+ of 7921) experience similar TTP and OS to YA (mTTP: 5.1 vs. 5.2mos; mOS 11.6 vs 12.4mos, respectively). Conclusions: We did not observe a statistical difference in survival outcomes by age following 2^nd line mCRC therapy. Further study is needed to examine unmeasured comorbidity and use of geriatric assessment to select OA likely to benefit from 2^nd line therapy. [Table: see text]